BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Otsuka, Lundbeck Tout Positive Phase III Results for Alzheimer’s Drug Brexpiprazole

  Otsuka Pharmaceutical and Lundbeck announced positive Phase III clinical trial results Monday regarding brexpiprazole (Rexulti) as a treatment for agitation in patients with Alzheimer’s dementia.

  June 27, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Exercise in a Pill: Key Molecules Identified that Decrease Hunger Post-Exercise

  For the exercise-phobic, a pill that would create the benefits of exercise without the work has been a pipe dream. Today, such a pill – actually, an “anti-hunger molecule” – is a bit closer to reality.

  June 27, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  Second UTHealth Study Suggests Flu Vaccine Offers Protection Against Alzheimer’s

  Collectively, the data set found that 5.1% of vaccinated patients went on to develop AD, while 8.5% of unvaccinated patients developed the disease.

  June 27, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Policy

  FDA Places Partial Clinical Hold on Nuvation’s Cancer Therapeutic

  Monday morning, Nuvation Bio announced that the U.S. Food and Drug Administration placed a partial clinical hold on its Phase I dose escalation study of NUV-422.

  June 27, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  GSK, Ionis Present “Potentially Transformative” Data from Hepatitis B Hopeful

  GSK and Ionis released promising trial data showing their investigational antisense oligonucleotide, bepirovirsen, could significantly reduce HBsAg and viral DNA levels in patients with CHB.

  June 27, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference

  For the first time in two years, the European Association for the Study of the Liver’s International Liver Congress was back on-site with cutting-edge research in hepatology and other sectors.

  June 27, 2022

   · 

  5 min read

   · 

  Tristan Manalac
• 

  Employer Resources

  Hiring in Life Sciences is Becoming More Difficult, Study Shows

  A report by CBRE shows that finding life sciences research talent may prove extremely difficult for employers. However, there are steps you can take to find top talent for these roles.

  June 27, 2022

   · 

  3 min read

   · 

  Rosemary Scott
• 

  Drug Development

  More Gene Therapy Trouble for Astellas as FDA Pauses Pompe Trial

  The FDA has placed Astellas Pharma’s Phase I/II FORTIS trial on clinical hold after one of its study participants experienced a serious adverse event.

  June 27, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Amidst Legal Battle, BMS’ CAR-T Therapy Scores Second FDA Approval

  BMS’ CAR-T therapy Breyanzi picked up a second approval from the FDA. The cancer drug was approved for the treatment of adult patients with large B-cell lymphoma.

  June 27, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Graphene “Tattoos” May Be the Future of Blood Pressure Monitoring

  Researchers have developed a graphene-based e-tattoo that measures blood pressure continuously and has several advantages over the traditional blood pressure cuff.

  June 27, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh